Cyto3D® Live-Dead Assay Kit allows for high-resolution assessment of cell viability in patient tumor slices, enhancing precision medicine and immunotherapy studies.

TheWell Bioscience recently published a research highlight from STAR Protocols, highlighting a publication by Chang et al.,titled ‘Protocol for a patient-derived preclinical platform to model tumor-immune interactions and evaluate therapeutic efficacy’.

In this study, researchers developed a patient-derived preclinical platform to model tumor-immune interactions and evaluate therapeutic efficacy. The platform integrates peripheral blood mononuclear cells (PBMCs) with patient-derived cancer tissue slices (PCTS) to establish a co-culture environment that simulates the human tumor microenvironment (TME). Cyto3D® Live-Dead Assay Kit played a pivotal role in assessing the viability of tumor slices before and during co-culture. By providing high-resolution imaging, Cyto3D® Live-Dead Assay Kit  allowed researchers to monitor cell health without disrupting the 3D structure of the tumor slices. This capability was crucial for ensuring the reliability of the co-culture system and for evaluating the effects of immune checkpoint inhibitors.